Visus Therapeutics is a clinical-stage pharmaceutical company based in Seattle, WA and Orange County, CA focused on developing innovative ophthalmic therapies. Its lead asset, BRIMOCHOL, is an investigational once-daily eye drop for presbyopia that combines two FDA‑approved drugs, carbachol and brimonidine. BRIMOCHOL has been studied in more than 200 patients across six clinical studies. Topline data from a Phase 2 study were expected in the second half of 2021 and, pending affirmative results, the company planned to immediately initiate pivotal Phase 3 studies. The company intends to use the new funds to advance clinical and commercial efforts for BRIMOCHOL and to support research and development of its early‑stage ophthalmic pipeline. Ben Bergo is co‑founder and CEO. Visus Therapeutics is a clinical-stage pharmaceutical company pursuing development of the world’s first presbyopia-correcting eye drop intended to last a minimum of eight hours. Its lead clinical candidate, BRIMOCHOL, is an investigational once-daily eye drop designed to correct the loss of near vision associated with presbyopia. The company operates offices in Seattle and Orange County, California, and is advancing a pipeline of early-stage ophthalmic product candidates. There are currently no FDA-approved medications for presbyopia, a condition that typically begins in the 40s and affects billions globally, including approximately 123 million adults in the U.S. Visus intends to use proceeds from its recent financing to advance the clinical development program for BRIMOCHOL.

Total raised

$56M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2021